A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor‐Positive Metastatic Triple‐Negative Breast Cancer

LESSONS LEARNED: The combination of enobosarm and pembrolizumab was well tolerated and showed a modest clinical benefit rate of 25% at 16 weeks. Future trials investigating androgen receptor‐targeted therapy in combination with immune checkpoint inhibitors are warranted. BACKGROUND: Luminal androgen...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncologist
Glavni autori: Yuan, Yuan, Lee, Jin Sun, Yost, Susan E., Frankel, Paul H., Ruel, Christopher, Egelston, Colt A., Guo, Weihua, Gillece, John D., Folkerts, Megan, Reining, Lauren, Highlander, Sarah K., Robinson, Kim, Padam, Simran, Martinez, Norma, Tang, Aileen, Schmolze, Daniel, Waisman, James, Sedrak, Mina, Lee, Peter P., Mortimer, Joanne
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons, Inc. 2020
Teme:
Clinical Trial Results
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7873338/
https://ncbi.nlm.nih.gov/pubmed/33141975
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13583
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items